Neurometrix Inc (NURO) 1.70 $NURO
Natus Medical (BABY) Hits 52-Week High on Bullish Trends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:05PM CST
Shares of Natus Medical Inc. (BABY) scaled a 52-week high of $35.93 on Dec 9 and closed a trifle lower at $35.70, representing a healthy year-to-date return of approximately 58.7%.
JNJ: 104.43 (-2.29), BABY: 34.84 (-0.41), ALOT: 14.51 (+0.04), NURO: 1.70 (-0.04)
NeuroMetrix Expands Intellectual Property for Wearable Pain Relief Technology
Business Wire - Wed Dec 10, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering unique aspects of the Company's wearable pain relief technology. The patent addresses an important element in the Company proprietary OptiTherapy(TM) technology that automatically controls nerve stimulation to optimize pain relief. In particular, the patent covers the automated calibration procedure that determines the appropriate stimulation level for each device user. The Company expects the patent to issue in mid-2015 and to extend patent protection into 2032. The technology is incorporated in the currently marketed prescription SENSUS(R) pain management device and in Quell(TM) which will be unveiled at the International Consumer Electronics Show (CES) in Las Vegas in January 2015.
NURO: 1.70 (-0.04)
NeuroMetrix to Participate in the Benchmark Micro Cap Discovery Conference
Business Wire - Mon Dec 08, 11:59AM CST
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be participating in the one-on-one Benchmark Micro Cap Discovery Conference which will be held at the Palmer House Hilton, Chicago, IL on Thursday, December 11, 2014 from 8:00am to 2:30pm. Dr. Gozani intends to provide a business update and discuss development progress on Quell(TM), the Company's over the counter wearable pain relief device which will be unveiled at the International Consumer Electronics Show (CES) in Las Vegas in January 2015. To schedule a one-on-one meeting with Dr. Gozani please e-mail vcuratola@benchmarkcompany.com or contact your Benchmark representative.
NURO: 1.70 (-0.04)
NeuroMetrix to Unveil Revolutionary Wearable Pain Relief Device at 2015 International Consumer Electronics Show
Business Wire - Wed Nov 19, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will unveil Quell(TM), the Company's wearable pain relief device at the International Consumer Electronics Show (CES) in Las Vegas in January 2015.
NURO: 1.70 (-0.04)
NeuroMetrix ups revenues 8% in Q3
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 12:44PM CDT
NURO: 1.70 (-0.04)
NeuroMetrix's (NURO) CEO Shai Gozani on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 10:31AM CDT
NURO: 1.70 (-0.04)
NeuroMetrix Q3 EPS of -$0.19
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:07AM CDT
NURO: 1.70 (-0.04)
NeuroMetrix Reports Third Quarter 2014 Financial Results and Business Highlights
Business Wire - Tue Oct 28, 6:00AM CDT
--Progress with over-the-counter wearable device to treat chronic pain
NURO: 1.70 (-0.04)
NeuroMetrix reports October 28
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 6:43AM CDT
NURO: 1.70 (-0.04)
NeuroMetrix, Inc. Announces Date for 2014 Third Quarter Financial Results Conference Call
Business Wire - Tue Oct 21, 6:00AM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue its 2014 third quarter financial results before the opening of the market on October 28, 2014. The Company will host a conference call at 8:00 a.m., Eastern Time on October 28, 2014 to discuss its financial results as well as business developments affecting the Company.
NURO: 1.70 (-0.04)
3 Breakout Stocks Under $10 for Your Watch List
at The Street - Wed Oct 08, 7:25AM CDT
Keep an eye on these under-$10 stocks for breakout trades.
RDNT: 8.56 (+0.03), NURO: 1.70 (-0.04), FSGI: 2.10 (+0.01)
NeuroMetrix Reports Publication of Study Demonstrating that DPNCheck is Effective at Detecting Diabetic Peripheral Neuropathy at all Stages of Severity
Business Wire - Thu Sep 25, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of results from a DPNCheck(R) study conducted at the Diabetes Research Unit of the Ipswich Hospital NHS Trust in the United Kingdom. The study by Sharma and colleagues titled "Assessment of Diabetic Neuropathy Using a Point-of-Care Nerve Conduction Device Shows Significant Associations With the LDIFLARE Method and Clinical Neuropathy Scoring" was published in the Journal of Diabetes Science and Technology and is available at:
NURO: 1.70 (-0.04)
NeuroMetrix CEO to Present at 29th Annual Meeting of Japan Society of Diabetic Complications
Business Wire - Tue Sep 23, 12:49PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D., Ph.D., NeuroMetrix President and Chief Executive Officer, will participate in the 29th Annual Meeting of The Japan Society of Diabetic Complications to be held in Tokyo on October 3 and 4, 2014. The Japan Society of Diabetic Complications is a part of The Japan Diabetes Society which was established in 1958 to promote diabetes-related academic research and treatment programs. The organization has over 16,000 members and works in collaboration with other international organizations including the International Diabetes Federation (IDF), the American Diabetes Association (ADA), and the European Association for the Study of Diabetes (EASD). The Annual Meeting of the Japan Society of Diabetic Complications is one of the major events of the Japan Diabetes Society.
NURO: 1.70 (-0.04)
NeuroMetrix Names Senior Executive to Lead Consumer Healthcare Initiative Frank McGillin - SVP and GM, Consumer
Business Wire - Wed Sep 03, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that it has appointed Frank McGillin as Senior Vice President and General Manager, Consumer. Mr. McGillin will be responsible for development of a consumer healthcare business built on the Company's wearable therapeutic technology for treatment of chronic pain which was recently cleared by the FDA for over-the-counter use without a prescription requirement.
NURO: 1.70 (-0.04)
NeuroMetrix to Present at Rodman & Renshaw Annual Global Investment Conference
Business Wire - Tue Sep 02, 2:51PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference at the New York Palace Hotel, New York, NY on September 8-10, 2014. Dr. Gozani intends to provide an update on the Company's business activities including the SENSUS(R) Pain Management System for chronic pain and sleep, and the Company's emerging consumer healthcare initiative.
NURO: 1.70 (-0.04)
Bacterin Announces the Appointment of New Board Member
GlobeNewswire - Wed Aug 13, 6:30AM CDT
Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of David Goodman, MD, MSE to the board of directors. Dr. Goodman brings extensive experience in executive management through previous roles as CEO of SEDLine and EVP of Business Development for Masimo (Nasdaq:MASI). The Board unanimously elected Dr. Goodman to fill the vacancy created by Mitchell Godfrey's recent resignation. Bacterin would like to thank Mr. Godfrey for his years of service and dedication to the Company.
MASI: 24.49 (-0.42), BONE: 2.83 (-0.01), NURO: 1.70 (-0.04)
NeuroMetrix Reports Second Quarter 2014 Financial Results and Business Highlights
Business Wire - Thu Jul 24, 6:00AM CDT
--FDA regulatory clearance for over-the-counter wearable technology to treat chronic pain
NURO: 1.70 (-0.04)
NeuroMetrix Marks 10th Year Anniversary of Listing on NASDAQ
Business Wire - Tue Jul 22, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ: NURO) reported today that it had reached the 10th anniversary of its initial listing on NASDAQ.
NURO: 1.70 (-0.04)
NeuroMetrix, Inc. Announces Date for 2014 Second Quarter Financial Results Conference Call
Business Wire - Thu Jul 17, 2:32PM CDT
NeuroMetrix, Inc. (the "Company" (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue its 2014 second quarter financial results before the opening of the market on July 24, 2014. The Company will host a conference call at 8:00 a.m., Eastern Daylight Time on July 24, 2014 to discuss its financial results as well as business developments affecting the Company.
NURO: 1.70 (-0.04)
Healthcare Companies Announce Upcoming Earnings Schedules, and Receive FDA Approvals and Clearances - Analyst Notes on WellPoint, Anacor, NeuroMetrix, Ophthotech and Emergent BioSolutions
PR Newswire - Fri Jul 11, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), NeuroMetrix Inc. (NASDAQ: NURO), Ophthotech Corporation (NASDAQ: OPHT) and Emergent BioSolutions, Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4686-100free.
EBS: 26.04 (-0.33), NURO: 1.70 (-0.04), OPHT: 48.83 (+1.19), ANAC: 33.86 (-0.82), WLP: 128.71 (+0.94)
Natus Medical (BABY) Hits 52-Week High on Bullish Trends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:05PM CST
Shares of Natus Medical Inc. (BABY) scaled a 52-week high of $35.93 on Dec 9 and closed a trifle lower at $35.70, representing a healthy year-to-date return of approximately 58.7%.
JNJ: 104.43 (-2.29), BABY: 34.84 (-0.41), ALOT: 14.51 (+0.04), NURO: 1.70 (-0.04)
NeuroMetrix Expands Intellectual Property for Wearable Pain Relief Technology
Business Wire - Wed Dec 10, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering unique aspects of the Company's wearable pain relief technology. The patent addresses an important element in the Company proprietary OptiTherapy(TM) technology that automatically controls nerve stimulation to optimize pain relief. In particular, the patent covers the automated calibration procedure that determines the appropriate stimulation level for each device user. The Company expects the patent to issue in mid-2015 and to extend patent protection into 2032. The technology is incorporated in the currently marketed prescription SENSUS(R) pain management device and in Quell(TM) which will be unveiled at the International Consumer Electronics Show (CES) in Las Vegas in January 2015.
NURO: 1.70 (-0.04)
NeuroMetrix to Participate in the Benchmark Micro Cap Discovery Conference
Business Wire - Mon Dec 08, 11:59AM CST
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be participating in the one-on-one Benchmark Micro Cap Discovery Conference which will be held at the Palmer House Hilton, Chicago, IL on Thursday, December 11, 2014 from 8:00am to 2:30pm. Dr. Gozani intends to provide a business update and discuss development progress on Quell(TM), the Company's over the counter wearable pain relief device which will be unveiled at the International Consumer Electronics Show (CES) in Las Vegas in January 2015. To schedule a one-on-one meeting with Dr. Gozani please e-mail vcuratola@benchmarkcompany.com or contact your Benchmark representative.
NURO: 1.70 (-0.04)
NeuroMetrix to Unveil Revolutionary Wearable Pain Relief Device at 2015 International Consumer Electronics Show
Business Wire - Wed Nov 19, 6:00AM CST
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will unveil Quell(TM), the Company's wearable pain relief device at the International Consumer Electronics Show (CES) in Las Vegas in January 2015.
NURO: 1.70 (-0.04)
NeuroMetrix ups revenues 8% in Q3
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 12:44PM CDT
NURO: 1.70 (-0.04)
NeuroMetrix's (NURO) CEO Shai Gozani on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 10:31AM CDT
NURO: 1.70 (-0.04)
NeuroMetrix Q3 EPS of -$0.19
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:07AM CDT
NURO: 1.70 (-0.04)
NeuroMetrix Reports Third Quarter 2014 Financial Results and Business Highlights
Business Wire - Tue Oct 28, 6:00AM CDT
--Progress with over-the-counter wearable device to treat chronic pain
NURO: 1.70 (-0.04)
NeuroMetrix reports October 28
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 6:43AM CDT
NURO: 1.70 (-0.04)
NeuroMetrix, Inc. Announces Date for 2014 Third Quarter Financial Results Conference Call
Business Wire - Tue Oct 21, 6:00AM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue its 2014 third quarter financial results before the opening of the market on October 28, 2014. The Company will host a conference call at 8:00 a.m., Eastern Time on October 28, 2014 to discuss its financial results as well as business developments affecting the Company. NURO: 1.70 (-0.04)
3 Breakout Stocks Under $10 for Your Watch List
at The Street - Wed Oct 08, 7:25AM CDT
Keep an eye on these under-$10 stocks for breakout trades.
RDNT: 8.56 (+0.03), NURO: 1.70 (-0.04), FSGI: 2.10 (+0.01)
NeuroMetrix Reports Publication of Study Demonstrating that DPNCheck is Effective at Detecting Diabetic Peripheral Neuropathy at all Stages of Severity
Business Wire - Thu Sep 25, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of results from a DPNCheck(R) study conducted at the Diabetes Research Unit of the Ipswich Hospital NHS Trust in the United Kingdom. The study by Sharma and colleagues titled "Assessment of Diabetic Neuropathy Using a Point-of-Care Nerve Conduction Device Shows Significant Associations With the LDIFLARE Method and Clinical Neuropathy Scoring" was published in the Journal of Diabetes Science and Technology and is available at:
NURO: 1.70 (-0.04)
NeuroMetrix CEO to Present at 29th Annual Meeting of Japan Society of Diabetic Complications
Business Wire - Tue Sep 23, 12:49PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D., Ph.D., NeuroMetrix President and Chief Executive Officer, will participate in the 29th Annual Meeting of The Japan Society of Diabetic Complications to be held in Tokyo on October 3 and 4, 2014. The Japan Society of Diabetic Complications is a part of The Japan Diabetes Society which was established in 1958 to promote diabetes-related academic research and treatment programs. The organization has over 16,000 members and works in collaboration with other international organizations including the International Diabetes Federation (IDF), the American Diabetes Association (ADA), and the European Association for the Study of Diabetes (EASD). The Annual Meeting of the Japan Society of Diabetic Complications is one of the major events of the Japan Diabetes Society.
NURO: 1.70 (-0.04)
NeuroMetrix Names Senior Executive to Lead Consumer Healthcare Initiative Frank McGillin - SVP and GM, Consumer
Business Wire - Wed Sep 03, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that it has appointed Frank McGillin as Senior Vice President and General Manager, Consumer. Mr. McGillin will be responsible for development of a consumer healthcare business built on the Company's wearable therapeutic technology for treatment of chronic pain which was recently cleared by the FDA for over-the-counter use without a prescription requirement.
NURO: 1.70 (-0.04)
NeuroMetrix to Present at Rodman & Renshaw Annual Global Investment Conference
Business Wire - Tue Sep 02, 2:51PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference at the New York Palace Hotel, New York, NY on September 8-10, 2014. Dr. Gozani intends to provide an update on the Company's business activities including the SENSUS(R) Pain Management System for chronic pain and sleep, and the Company's emerging consumer healthcare initiative.
NURO: 1.70 (-0.04)
Bacterin Announces the Appointment of New Board Member
GlobeNewswire - Wed Aug 13, 6:30AM CDT
Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of David Goodman, MD, MSE to the board of directors. Dr. Goodman brings extensive experience in executive management through previous roles as CEO of SEDLine and EVP of Business Development for Masimo (Nasdaq:MASI). The Board unanimously elected Dr. Goodman to fill the vacancy created by Mitchell Godfrey's recent resignation. Bacterin would like to thank Mr. Godfrey for his years of service and dedication to the Company.
MASI: 24.49 (-0.42), BONE: 2.83 (-0.01), NURO: 1.70 (-0.04)
NeuroMetrix Reports Second Quarter 2014 Financial Results and Business Highlights
Business Wire - Thu Jul 24, 6:00AM CDT
--FDA regulatory clearance for over-the-counter wearable technology to treat chronic pain
NURO: 1.70 (-0.04)
NeuroMetrix Marks 10th Year Anniversary of Listing on NASDAQ
Business Wire - Tue Jul 22, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ: NURO) reported today that it had reached the 10th anniversary of its initial listing on NASDAQ.
NURO: 1.70 (-0.04)
NeuroMetrix, Inc. Announces Date for 2014 Second Quarter Financial Results Conference Call
Business Wire - Thu Jul 17, 2:32PM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue its 2014 second quarter financial results before the opening of the market on July 24, 2014. The Company will host a conference call at 8:00 a.m., Eastern Daylight Time on July 24, 2014 to discuss its financial results as well as business developments affecting the Company. NURO: 1.70 (-0.04)
Healthcare Companies Announce Upcoming Earnings Schedules, and Receive FDA Approvals and Clearances - Analyst Notes on WellPoint, Anacor, NeuroMetrix, Ophthotech and Emergent BioSolutions
PR Newswire - Fri Jul 11, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), NeuroMetrix Inc. (NASDAQ: NURO), Ophthotech Corporation (NASDAQ: OPHT) and Emergent BioSolutions, Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4686-100free.
EBS: 26.04 (-0.33), NURO: 1.70 (-0.04), OPHT: 48.83 (+1.19), ANAC: 33.86 (-0.82), WLP: 128.71 (+0.94)
